Gastric volvulus is a rare entity defined as an abnormal rotation of the stomach around itself. It is a diagnosis of exclusion; the clinical index of suspicion is always low and is mostly diagnosed on imaging or on the surgery table. When it occurs, it is an emergency due to the risk of strangulation and consequent gangrene of the stomach. Mesentero-axial (MA) gastric volvuli constitute one-third of all cases. Here, we are present an interesting case of acute MA gastric volvulus diagnosed with imaging and treated subsequently.
Coronavirus-19, primarily a respiratory virus, also affects the nervous system. Acute ischemic stroke (AIS) is a well-known complication among COVID-19 infections, but large-scale studies evaluating AIS outcomes related to COVID-19 infection remain limited. We used the National Inpatient Sample database to compare acute ischemic stroke patients with and without COVID-19. A total of 329,240 patients were included in the study: acute ischemic stroke with COVID-19 (n = 6665, 2.0%) and acute ischemic stroke without COVID-19 (n = 322,575, 98.0%). The primary outcome was in-hospital mortality. Secondary outcomes included mechanical ventilation, vasopressor use, mechanical thrombectomy, thrombolysis, seizure, acute venous thromboembolism, acute myocardial infarction, cardiac arrest, septic shock, acute kidney injury requiring hemodialysis, length of stay, mean total hospitalization charge, and disposition. Acute ischemic stroke patients who were COVID-19-positive had significantly increased in-hospital mortality compared to acute ischemic stroke patients without COVID-19 (16.9% vs. 4.1%, aOR: 2.5 [95% CI 1.7-3.6], p < 0.001). This cohort also had significantly increased mechanical ventilation use, acute venous thromboembolism, acute myocardial infarction, cardiac arrest, septic shock, acute kidney injury, length of stay, and mean total hospitalization charge. Further research regarding vaccination and therapies will be vital in reducing worse outcomes in patients with acute ischemic stroke and COVID-19.
Study the association between the introduction of tobacco control policies in the Netherlands and changes in perinatal outcomes.National quasi-experimental study.We used Netherlands Perinatal Registry data (now called Perined) for the period 2000-2011. We studied whether the introduction of smoke-free legislation in workplaces plus a tobacco tax increase and mass media campaign in January 2004, and extension of the smoke-free law to the hospitality industry accompanied by another tax increase and media campaign in July 2008, was associated with changes in perinatal outcomes. We studied all singleton births (gestational age: 24+0 to 42+6 weeks). Our primary outcome measures were: perinatal mortality, preterm birth and being small-for-gestational-age (SGA). Interrupted time series logistic regression analyses were performed to investigate changes in these outcomes occurred after the introduction of the aforementioned tobacco control policies (ClinicalTrials.gov: NCT02189265).Among 2,069,695 singleton births, 13,027 (0.6%) perinatal deaths, 116,043 (5.6%) preterm live-births and 187,966 (9.1%) SGA live-births were observed. The policies introduced in January 2004 were not associated with significant changes in any of the primary outcome measures. A -4.4% (95% CI: -6.4 to -2.4; p < 0.001) decrease in odds of a SGA birth was observed after the policy extension in July 2008 to include a smoke-free hospitality industry, a further tax increase and another media campaign. This translates to an estimated over 500 cases of SGA being averted per year.A reduction in SGA births, but not preterm birth or perinatal mortality, was observed in the Netherlands after extension of the smoke-free workplace law to include bars and restaurants, in conjunction with a tax increase and media campaign in 2008.
Abstract AIM Despite the obvious advantages of intraoperative sentinel lymph node (SLN) analysis in the form of One Step Nucleic Acid Amplification (OSNA), this technique has not been widely adopted in the United Kingdom. The aim of this study was to investigate the health economic implication of the technique. METHODS Data were collected prospectively on all patients undergoing OSNA at a single institution between September 2011 and February 2013. Initially patients were selected using the Sloan Kettering Nomogram for additional non SLN axillary disease [http://nomograms.mskcc.org] and patients with micrometastases were offered an axillary clearance. From August 2012, all patients undergoing sentinel node biopsy were offered OSNA. A cost analysis was done on the basis of up front purchase costs, OSNA cost per patient minus the cost of standard Haematoxylin and Eosin stain analyses at our institution and HRG4 codes. RESULTS Data were collected on 258 patients with a median age of 69. 209 (81%) had invasive ductal carcinoma. 208(80%) were oestrogen receptor positive and approximately 30% had lymphovascular invasion. Table 2 demonstrates the OSNA results. Table 1 - OSNA results Pre August 2012Post August 2012Total n%n%n%No. of patients169 88 257 Mean no. of nodes2.38 1.98 2.24 OSNA Negative11668.645461.3617066.15OSNA Micrometastases2715.982123.864818.68OSNA Macrometastases2112.431314.773413.23OSNA Inhibited52.960051.95Total no. undergoing Axillary Clearance5130.181820.456926.85Axillary Clearance for Micrometastases2313.6144.552710.51Additional nodes positive overall: 03772.55950.004666.671-3 nodes1121.57738.891826.094-7 nodes11.96211.1134.358-12 nodes11.96 11.45gt]12 nodes[11.96 11.45Additional nodes positive for OSNA Micrometastases: 021 22385.191-3 nodes2 414.81 The capital investment for setting up OSNA in our institution was £40,000. By carrying out OSNA on all patients undergoing sentinel node biopsy we saved a second procedure on 20% of patients. Table 2 outlines the costs saving per year based on the HRG4 code for the cost of second admission and axillary clearance. Table 2 - Health Economic Analysis TotalNo. patients undergoing OSNA per year235 Cost of OSNA per patient£286£67,210Cost of H & E analysis based on 2 nodes per patient£101,60£23,876Net costs of OSNA per patient£184,40£43,334No. patients undergoing axillary clearance (20% of 235)47 Cost of axillary clearance (based on HRG4 JA07)£2,030£95,410Total saving per year with OSNA £52,076 CONCLUSION The use of OSNA as an intraoperative assessment of sentinel lymph nodes in breast cancer is a highly sensitive and efficient way of determining the sentinel node status. It saves patients undergoing a second admission and procedure. By offering OSNA to all patients undergoing SLN, the capital investment will be recouped in less than a year and the local health economy will save over £50,000 per year in subsequent years. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-01-11.
Infective endocarditis in drug users commonly targets the tricuspid valves, whereas pulmonic valve endocarditis is a rare occurrence. Staphylococcus aureus rather than Streptococcus species is the culprit organism. Streptococcal pneumonia is also not commonly seen as an etiological agent for endocarditis. Here we present a case of a 57-year-old man with a history of HIV infection on antiretroviral therapy who was admitted for sepsis and found to have pneumococcal bacteremia with vegetation on a pulmonic valve. He had been vaccinated with both pneumococcal conjugate vaccine 13 and pneumococcal polysaccharide vaccine 23 at the time of his HIV diagnosis. Pulmonic valve endocarditis is unusual in the setting of pneumococcal bacteremia in HIV patients previously vaccinated for pneumococcal disease.
An amoebic liver abscess is an extraintestinal manifestation of amoebiasis that can present with complaints such as right upper quadrant pain and fever. It might not necessarily be associated with abdominal complaints and can have many other atypical presentations. It may present with lung diseases, cardiac diseases, or brain abscesses. We present a case of a patient with empyema secondary to amoebic liver abscess whose diagnosis was delayed due to an unusual presentation. A combination of radiology, serology, and therapeutic interventions led to the accurate management of the patient.
Seasonal epidemics of respiratory syncytial virus (RSV) is one of the leading causes of hospitalization and mortality among children. Preventive measures implemented to reduce the spread of SARS-CoV-2, including facemasks, stay-at-home orders, closure of schools and local-national borders, and hand hygiene, may have also prevented the transmission of RSV and influenza. However, with the easing of COVID-19 imposed restrictions, many regions are noticing a delayed RSV outbreak. Some of these regions have also noted an increase in severity of these delayed RSV outbreaks partly due to a lack of protective immunity in the community following a lack of exposure from the previous season. Lessons learned from the COVID-19 pandemic can be implemented for controlling RSV outbreaks, including: (1) measures to reduce the spread, (2) effective vaccine development, and (3) genomic surveillance tools and computational modeling to predict the timing and severity of RSV outbreaks. These measures can help reduce the severity and prepare the health care system to deal with future RSV outbreaks by appropriate and timely allocation of health care resources.
: This retrospective study aims to examine the patient demographics, survival rates, and treatment methods for small-cell neuroendocrine carcinoma (SCNEC) and large-cell neuroendocrine carcinoma (LCNEC) of prostate origin while also identifying the main differences between common types of prostate cancer with comparative analysis for survival.
'/%3e%3cpath fill='%23fff' d='m8.751-17.959 10.11 11.373L3.997-9.844l13.94-6.1-7.692 13.129z'/%3e%3c/svg%3e)